None listed
Conditions
Interventions
Patients with atrial fibrillation who have undergone radiofrequency ablation surgery and are receiving anticoagulation therapy with rivaroxaban.:NA
Sponsors
Huzhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years, gender not specified; 2. Meet the diagnostic criteria for non-valvular atrial fibrillation according to the 2020 European Society of Cardiology (ESC) guidelines, which include a standard 12-lead ECG recording or a single-lead ECG recording of at least 30 seconds with the disappearance of P waves and irregular RR intervals (without impaired atrioventricular conduction), and have clinical symptoms, and are stable patients receiving radiofrequency ablation for atrial fibrillation and taking rivaroxaban 15 or 20 mg (once a day, qd) anticoagulation therapy at our hospital; 3. After being fully informed, voluntarily sign the clinical biological sample collection informed consent form of our hospital.
Exclusion criteria
Exclusion criteria: 1. Patients who are taking any other anticoagulant drugs or who are using ketoconazole, cyclosporine, etc., which interfere with the metabolism of rivaroxaban; 2. Patients who do not adhere to the treatment regimen; 3. Patients who do not undergo follow-up checks at our hospital at the specified time during their treatment; 4 .Patients who are unable or unwilling to cooperate with the collection of clinical information (e.g., patients with mental disorders, memory disorders, etc.); 5. Patients who, in the judgment of the research team, have other conditions that are not appropriate for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma concentration;Gene polymorphism;Laboratory indicators;concomitant medication; | — |
Secondary
| Measure | Time frame |
|---|---|
| Basic information of patients; | — |
Countries
China
Contacts
Public ContactGu Fangfang
Huzhou Central Hospital
Outcome results
None listed